Incretin therapy for diabetes mellitus type 2

Dec 10, 2019Current opinion in endocrinology, diabetes, and obesity

Incretin treatments for type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists (GLP-1RAs) are currently the most efficacious agents for weight loss.

GLP-1RAs may improve glycemic control and reduce cardiovascular and renal risks.
Recent developments include orally available agonists and potent co-agonists targeting both GLP-1 and GIP receptors.
GLP-1RAs could be enhanced in efficacy when combined with other food-intake-regulating peptides.
Their therapeutic efficacy is significant for the treatment of type 2 diabetes and obesity.

AI simplified

PURPOSE OF REVIEW: Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. New agonists and formulations of particularly the GLP-1 receptor have been developed recently showing great therapeutic efficacy for both diseases.

RECENT FINDINGS: The status of the currently available GLP-1 receptor agonists (GLP-1RAs) is described, and their strengths and weaknesses analyzed. Their ability to also reduce cardiovascular and renal risk is described and analysed. The most recent development of orally available agonists and of very potent monomolecular co-agonists for both the GLP-1 and GIP receptor is also discussed.

SUMMARY: The GLP-1RAs are currently the most efficacious agents for weight loss, and show potential for further efficacy in combination with other food-intake-regulating peptides. Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.

Full Text

Full text is available at the source.

View full text ↗

Incretin therapy for diabetes mellitus type 2

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief